7-24-2020Cross-posted from NIAID NewsroomNIAID Celebrates Pivotal Step Toward Expanding HIV Prevention Choices for WomenToday the European Medicines Agency (EMA) announc…
7-24-2020Cross-posted from NIAID NewsroomMulticenter HOPE Act Study Expands Pool of Available KidneysKidney transplantation from deceased donors with HIV to people livin…
7-21-2020Cross-posted from NIAID NewsroomThe National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and IAVI, a nonprofit scie…
7-7-2020Cross-posted from NIAID NewsroomBoth Methods Highly Effective at Preventing HIV Among Men Who Have Sex with Men and Transgender WomenA pre-exposure prophylaxis …
5-18-2020Cross-posted from NIAID NewsroomNIH Study is First Large Trial to Find Long-Acting HIV Prevention Highly Effective--Companion Study in Women Is OngoingAn invest…
5-18-2020NIAID honors ongoing efforts to develop a safe, effective and durable HIV vaccine while scientists also research coronavirus disease 2019 (COVID-19).
5-15-2020Cross-posted from NIAID NewsroomStudy Enrolling Adults with Mild to Moderate COVID-19 in the United States.Adults interested in participating in the trial shoul…
3-11-2020Cross-posted from NIAID NewsroomDolutegravir-containing regimen exhibited superior safety profile in large, NIH-supported study of pregnant women.The antiretrov…
3-9-2020Cross-posted from NIAID NewsroomAmong African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenof…
3-9-2020Cross-posted from NIAID NewsroomThe cancer drug paclitaxel and a suppressive regimen of antiretroviral therapy (ART) is an effective treatment for AIDS-related …
